Loading...
OTCM
BPMUF
Market cap655mUSD
Apr 22, Last price  
47.50
Name

Basilea Pharmaceutica AG Allschwil

Chart & Performance

D1W1MN
P/E
—
P/S
—
EPS
6.40
Div Yield, %
—
Shrs. gr., 5y
5.19%
Rev. gr., 5y
9.19%
Revenues
209m
+32.30%
30,494,9207,183,7807,898,45011,974,20826,828,225115,555,21466,149,58958,335,75240,950,66842,499,00052,825,00065,983,999101,521,000132,555,000134,381,000127,629,000148,122,000147,765,000157,634,000208,543,000
Net income
78m
+642.45%
-49,595,730-85,149,690-126,819,540-143,528,034-120,736,494107,564,085-57,645,627-53,033,105-33,019,931-41,546,000-61,603,000-51,287,000-19,360,000-31,352,000-22,422,000-14,722,000-6,831,00012,147,00010,451,00077,593,000
CFO
74m
+422.03%
34,380,170-72,465,080-78,987,770-127,165,900-114,510,110106,635,957-82,376,566148,174,455-59,469,815-71,461,000-67,780,000-75,003,00019,014,000-79,210,000-63,836,000-54,134,000-32,020,0007,056,00014,245,00074,363,000
Earnings
Aug 11, 2025

Profile

Basilea Pharmaceutica AG, a commercial stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. It offers Cresemba, an intravenous and oral azole antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union, as well as in Phase III clinical trials for invasive fungal infections in Japan. The company also provides Zevtera, an antibiotic for the treatment of community and hospital-acquired pneumonia, as well as in Phase III clinical trials for the treatment of acute bacterial skin and skin structure infections, and Staphylococcus aureus bacteremia. In addition, it engages in developing Derazantinib, a small molecule inhibitor, which is in phase 2 clinical trial for bile duct cancer, as well as in phase ½ clinical trial for bladder and stomach cancer; and Lisavanbulin, a tumor checkpoint controller drug. Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Basel, Switzerland.
URL
https://www.basilea.com/
IPO date
Mar 25, 2004
Employees
143
Domiciled in
CH
Incorporated in
CH

Valuation

Title
CHF in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
208,543
32.30%
157,634
6.68%
147,765
-0.24%
Cost of revenue
224,509
138,429
162,237
Unusual Expense (Income)
NOPBT
(15,966)
19,205
(14,472)
NOPBT Margin
12.18%
Operating Taxes
(17,333)
10
(45)
Tax Rate
0.05%
NOPAT
1,367
19,195
(14,427)
Net income
77,593
642.45%
10,451
-13.96%
12,147
-277.82%
Dividends
Dividend yield
Proceeds from repurchase of equity
2,439
2,009
4,426
BB yield
-0.43%
-0.47%
-0.81%
Debt
Debt current
2,062
17,515
39,455
Long-term debt
125,368
128,789
147,683
Deferred revenue
9,460
10,693
Other long-term liabilities
21,598
15,149
8,337
Net debt
6,719
86,404
77,305
Cash flow
Cash from operating activities
74,363
14,245
7,056
CAPEX
(1,710)
(813)
(3,303)
Cash from investing activities
(1,011)
(1,034)
91,649
Cash from financing activities
(13,164)
(57,305)
(45,246)
FCF
8,383
11,448
(45,371)
Balance
Cash
120,711
59,900
86,567
Long term investments
23,266
Excess cash
110,284
52,018
102,445
Stockholders' equity
(910,123)
(997,997)
(1,001,764)
Invested Capital
1,124,391
1,141,209
1,169,894
ROIC
0.12%
1.66%
ROCE
13.41%
EV
Common stock shares outstanding
13,855
12,143
11,944
Price
41.35
17.14%
35.30
-22.93%
45.80
11.93%
Market cap
572,906
33.65%
428,651
-21.64%
547,013
14.43%
EV
579,625
515,055
624,318
EBITDA
(11,834)
22,682
(11,375)
EV/EBITDA
22.71
Interest
4,344
11,202
11,011
Interest/NOPBT
58.33%